VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 126 filers reported holding VIRIDIAN THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,748,000 | -35.5% | 2,200,000 | 0.0% | 3.94% | -32.9% |
| Q2 2023 | $52,338,000 | -6.0% | 2,200,000 | +0.5% | 5.88% | -30.6% |
| Q1 2023 | $55,704,925 | +94300.7% | 2,189,659 | +8.4% | 8.48% | -4.6% |
| Q4 2022 | $59,009 | -99.9% | 2,020,166 | -25.1% | 8.89% | 0.0% |
| Q3 2022 | $55,302,000 | +191.7% | 2,696,340 | +64.6% | 8.89% | +121.9% |
| Q2 2022 | $18,959,000 | +7.8% | 1,638,609 | +72.2% | 4.01% | +2.0% |
| Q1 2022 | $17,590,000 | +5.0% | 951,339 | +12.2% | 3.93% | +1.2% |
| Q4 2021 | $16,759,000 | +52.6% | 847,683 | +27.0% | 3.88% | +34.0% |
| Q3 2021 | $10,983,000 | +222.2% | 667,674 | +258.2% | 2.90% | +143.8% |
| Q2 2021 | $3,409,000 | +9.8% | 186,405 | +0.3% | 1.19% | -3.9% |
| Q1 2021 | $3,104,000 | – | 185,781 | – | 1.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,082,622 | $47,287,421 | 4.98% |
| COMMODORE CAPITAL LP | 2,200,000 | $33,748,000 | 3.94% |
| Paradigm Biocapital Advisors LP | 3,681,747 | $56,477,999 | 3.83% |
| Vivo Capital, LLC | 1,678,207 | $25,743,695 | 2.82% |
| Fairmount Funds Management LLC | 1,369,623 | $21,010,017 | 2.53% |
| Octagon Capital Advisors LP | 1,067,143 | $16,369,974 | 2.52% |
| ACUTA CAPITAL PARTNERS, LLC | 224,339 | $3,441,360 | 2.31% |
| Logos Global Management LP | 1,050,000 | $16,107,000 | 2.15% |
| Kopp Family Office, LLC | 214,290 | $3,287 | 2.08% |
| 5AM Venture Management, LLC | 410,000 | $6,289,400 | 1.81% |